» Articles » PMID: 23671189

Tumor Necrosis Factor α-induced Hypoxia-inducible Factor 1α-β-catenin Axis Regulates Major Histocompatibility Complex Class I Gene Activation Through Chromatin Remodeling

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2013 May 15
PMID 23671189
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the progression of glioblastoma multiforme tumors, which are characterized by their effective immune escape mechanisms. As major histocompatibility complex class I (MHC-I) is involved in glioma immune evasion and since HIF-1α is a pivotal link between inflammation and glioma progression, the role of tumor necrosis factor alpha (TNF-α)-induced inflammation in MHC-I gene regulation was investigated. A TNF-α-induced increase in MHC-I expression and transcriptional activation was concurrent with increased HIF-1α, ΝF-κΒ, and β-catenin activities. While knockdown of HIF-1α and β-catenin abrogated TNF-α-induced MHC-I activation, NF-κB had no effect. β-Catenin inhibition abrogated HIF-1α activation and vice versa, and this HIF-1α-β-catenin axis positively regulated CREB phosphorylation. Increased CREB activation was accompanied by its increased association with β-catenin and CBP. Chromatin immunoprecipitation revealed increased CREB enrichment at CRE/site α on the MHC-I promoter in a β-catenin-dependent manner. β-Catenin replaced human Brahma (hBrm) with Brg1 as the binding partner for CREB at the CRE site. The hBrm-to-Brg1 switch is crucial for MHC-I regulation, as ATPase-deficient Brg1 abolished TNF-α-induced MHC-I expression. β-Catenin also increased the association of MHC-I enhanceosome components RFX5 and NF-YB at the SXY module. CREB acts as a platform for assembling coactivators and chromatin remodelers required for MHC-I activation in a HIF-1α/β-catenin-dependent manner.

Citing Articles

Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review.

Begagic E, Beculic H, Dzidic-Krivic A, Kadic Vukas S, Hadzic S, Mekic-Abazovic A Cancers (Basel). 2024; 16(11).

PMID: 38893207 PMC: 11171068. DOI: 10.3390/cancers16112089.


PRMT1 driven PTX3 regulates ferritinophagy in glioma.

Lathoria K, Gowda P, Umdor S, Patrick S, Suri V, Sen E Autophagy. 2023; 19(7):1997-2014.

PMID: 36647288 PMC: 10283415. DOI: 10.1080/15548627.2023.2165757.


Extracellular Events Involved in Cancer Cell-Cell Fusion.

Dittmar T, Hass R Int J Mol Sci. 2022; 23(24).

PMID: 36555709 PMC: 9784959. DOI: 10.3390/ijms232416071.


Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma.

Lv S, Chen Z, Mi H, Yu X Cancer Manag Res. 2022; 14:3245-3269.

PMID: 36452435 PMC: 9703913. DOI: 10.2147/CMAR.S389825.


Multiple Faces of the Glioblastoma Microenvironment.

Sovrea A, Bosca B, Melincovici C, Constantin A, Crintea A, Marginean M Int J Mol Sci. 2022; 23(2).

PMID: 35054779 PMC: 8775531. DOI: 10.3390/ijms23020595.


References
1.
Ogiwara H, Ui A, Otsuka A, Satoh H, Yokomi I, Nakajima S . Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene. 2011; 30(18):2135-46. DOI: 10.1038/onc.2010.592. View

2.
Sharma V, Dixit D, Koul N, Mehta V, Sen E . Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J Mol Med (Berl). 2010; 89(2):123-36. DOI: 10.1007/s00109-010-0683-5. View

3.
Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T, Thanos D . Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell. 2000; 103(4):667-78. DOI: 10.1016/s0092-8674(00)00169-0. View

4.
Christova R, Jones T, Wu P, Bolzer A, Costa-Pereira A, Watling D . P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma. J Cell Sci. 2007; 120(Pt 18):3262-70. DOI: 10.1242/jcs.012328. View

5.
Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O . A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004; 64(4):1338-46. DOI: 10.1158/0008-5472.can-03-2089. View